Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Net Income (2022 - 2025)

Historic Net Income for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.

  • Zentalis Pharmaceuticals' Net Income rose 3353.5% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 1673.86%. This contributed to the annual value of -$165.9 million for FY2024, which is 3996.66% up from last year.
  • Zentalis Pharmaceuticals' Net Income amounted to -$26.7 million in Q3 2025, which was up 3353.5% from -$26.9 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Net Income high stood at $10.0 million for Q1 2024, and its period low was -$98.9 million during Q2 2023.
  • Its 4-year average for Net Income is -$51.0 million, with a median of -$52.1 million in 2022.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Net Income surged by 11647.2% in 2024, and later tumbled by 58086.65% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Net Income (Quarter) stood at -$48.2 million in 2022, then dropped by 26.53% to -$60.9 million in 2023, then increased by 22.1% to -$47.5 million in 2024, then surged by 43.78% to -$26.7 million in 2025.
  • Its Net Income was -$26.7 million in Q3 2025, compared to -$26.9 million in Q2 2025 and -$48.3 million in Q1 2025.